KLCM Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

KLCM Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,000	Closed	-$285	–	175
2024 Q2	$285	Hold	30,000	–	–	﹤0.01%	159
2024 Q1	$240	Hold	30,000	–	–	﹤0.01%	160
2023 Q4	$3.71K	Buy	30,000 +10,000	+50%	+$1.24K	﹤0.01%	153
2023 Q3	$1.88K	Hold	20,000	–	–	﹤0.01%	135
2023 Q2	$7.16K	Hold	20,000	–	–	﹤0.01%	137
2023 Q1	$7.2K	Hold	20,000	–	–	﹤0.01%	127
2022 Q4	$17.7K	Buy	+20,000	New	+$26.5K	﹤0.01%	124

Other funds holding SRNE

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

HAG

HighPoint Advisor Group Downers Grove, Illinois $2.84B AUM 31.94% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

KLCM Advisors's SRNE Position: Q3 2024 in Review

KLCM Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2024, closing a stake of 30,000 shares — an estimated $285 sold.

KLCM Advisors first reported a position in SRNE in Q4 2022 and held it in 7 quarters. The position peaked at $17.7K in Q4 2022. 4 funds tracked by Wall St. Rank hold SRNE as of Q3 2024.

KLCM Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
KLCM Advisors sold 30,000 Sorrento Therapeutics, Inc. shares in Q3 2024, an estimated $285.
KLCM Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 7 quarters.
KLCM Advisors's Sorrento Therapeutics, Inc. position peaked at $17.7K in Q4 2022.
4 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2024.

Based on KLCM Advisors's 13F filing for Q3 2024, filed 7 Nov 2024.